Norgestrel

Summary

Norgestrel (CHEMBL2107797) is an approved small molecule; indicated across 2 conditions including endometrium neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 3
• Chemistry: 312.4 Da · C21H28O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107797
Name	Norgestrel
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	16051930
Molecular formula	C21H28O2
Molecular weight	312.4
InChIKey	WWYNJERNGUHSAO-CULCCENASA-N

SMILES: CC[C@]12CC[C@H]3[C@H]([C@@H]1CCC2(C#C)O)CCC4=CC(=O)CC[C@H]34

IUPAC name: (8R,9S,10R,13S,14S)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one

Also known as: Dl-norgestrel, FH-122A, Norgestrel, Norgestrel component of cryselle, Norgestrel component of ovral, NSC-757251, Opill, Ovrette, Prefest, Previfem, SH-70850, SH-850

Patent coverage: 3,073 distinct patent families (10,747 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 8 (assay-derived). Sample: Prelamin-A/C, Beta-lactamase, Glucocorticoid receptor, Menin/Histone-lysine N-methyltransferase MLL, Sodium-dependent serotonin transporter, DNA polymerase beta, Androgen receptor, Sex hormone-binding globulin.

Bioactivity

ChEMBL activities: 9 potent at pChembl ≥ 5 of 12 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SHBG	8.91	Kd	1.23	nM	CHEMBL_ACT_2155735
P15207	8.37	Ki	4.27	nM	CHEMBL_ACT_7737937
P15207	8.19	IC50	6.4	nM	CHEMBL_ACT_7737936
P15207	7.73	IC50	18.62	nM	CHEMBL_ACT_1605632
NR3C1	7.17	Ki	68	nM	CHEMBL_ACT_7735789
NR3C1	6.83	IC50	149	nM	CHEMBL_ACT_7735788
SLC6A4	6.22	Ki	595	nM	CHEMBL_ACT_7737925
SLC6A4	5.95	IC50	1119	nM	CHEMBL_ACT_7737924
LMNA	5.55	Potency	2818	nM	CHEMBL_ACT_3639378

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
endometrium neoplasm	2	MONDO:0021251	MONDO:0011962

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE2	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00033358	PHASE2	COMPLETED	Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer
NCT03585712	PHASE2	COMPLETED	Effect of Norgestrel 75 mcg on Cervical Mucus and Ovarian Activity During Perfect Use, After One Delayed Intake and After a Missed Pill
NCT05742503	Not specified	COMPLETED	Progesterone Containing Contraceptive Methods on Endogenous Progesterone Level

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).